« Students sign awareness; Event focuses on sign language | Main | Interpreter Served as Lifeline to Deaf Community During Fires »
November 1, 2007
OHSU hearing loss preventative in final test phase
Adherex Technologies Inc. has begun the final phase of clinical testing of a treatment developed by Oregon Health & Science University to prevent hearing loss in children undergoing chemotherapy for liver cancer.
Preliminary studies by OHSU scientists suggest that sodium thiosulfate, or STS, can reduce the hearing loss associated with platinum-based chemotherapy. On Tuesday, Adherex said the phase III study will compare the outcomes of children treated with the cancer drug cisplatin alone or in combination with STS.
The United Kingdom-based Children's Cancer and Leukaemia Group is coordinating the multi-center study.
OHSU licensed its intellectual property rights on STS to Adherex, a publicly traded startup in Research Triangle Park, N.C. OHSU holds shares in the company.
The U.S. Food and Drug Administration granted Adherex an orphan drug designation on the use of the drug to prevent hearing loss. The compound has long been approved for treating cyanide poisoning.
http://blog.oregonlive.com/business/2007/10/ohsu_hearing_loss_treatment_he.html
Posted by 4HL on November 1, 2007 3:57 AM
Send this article to a friend